JaLCDOI 10.18926/AMO/56249
フルテキストURL 72_5_507.pdf
著者 Ogata, Takeshi| Katsui, Kuniaki| Yoshio, Kotaro| Ihara, Hiroki| Katayama, Norihisa| Soh, Junichi| Kuroda, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu|
抄録 To clarify the relationship between dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) after surgery in cases of non-small cell lung cancer (NSCLC) treated with induction concurrent chemoradiotherapy (CCRT). Patients with NSCLC treated with induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 2.0 Gy fractions once daily for a total of 46 Gy) before surgery were reviewed. We calculated the percentage of lung volume receiving at least 20 Gy (V20) and the mean lung dose (MLD) for the total lung volume and the lung remaining after resection. Factors affecting the incidence of RP at grade 2 or higher (≥ G2 RP) were analyzed. Eighteen of 49 patients (37%) experienced ≥G2 RP. The V20 and MLD for the lung remaining after resection (V20r and MLDr) were significant predictors according to the multivariate analysis (p=0.007 and 0.041, respectively). The incidence of ≥G2 RP was 8% in patients with V20r<10%, and 13% in patients with MLDr<5.6 Gy, respectively. The optimal approach to reduce the rate of postoperative RP in patients with induction CCRT for NSCLC is to keep the V20r below 10% and/or the MLDr below 5.6 Gy in the radiotherapy planning.
キーワード radiation pneumonitis V20 mean lung dose induction chemoradiotherapy non-small cell lung cancer
Amo Type Original Article
発行日 2018-10
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 507
終了ページ 513
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30369608
著者 Waki, Takahiro| Katsui, Kuniaki| Mitsuhashi, Toshiharu| Ogata, Takeshi| Katayama, Norihisa| Takemoto, Mitsuhiro| Nasu, Yasutomo| Kumon, Hiromi| Kanazawa, Susumu|
発行日 2017-02
出版物タイトル Acta Medica Okayama
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/54823